Could a common blood thinner help ventilated COVID-19 patients breathe easier?
NCT ID NCT04545541
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether giving nebulised heparin (a blood thinner delivered as a mist) to COVID-19 patients on mechanical ventilation could help them get off the breathing machine sooner and reduce deaths. The trial combined data from several smaller studies in Australia, Ireland, the US, and the UK, involving 57 adults in intensive care. Patients received either heparin or standard care/placebo for up to 10 days while on a ventilator.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nebulised heparin (a blood thinner given as a mist into the lungs)
- What this could lead to
- If it works, this could point toward a simple, low-cost treatment to help COVID-19 patients on ventilators recover faster and need less breathing support.
- What could go wrong
- This is a small, early-stage analysis of several trials, so results may not be definitive. Heparin can increase bleeding risk, especially in critically ill patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
57 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Currently in an intensive care unit (ICU) or scheduled for transfer to the ICU. During the pandemic, critically ill inpatients might be cared for outside of the walls of the usual physical environment of ICU. For this reason, ICU is defined as an area designated for inpatient care of the critically ill where therapies including invasive mechanical ventilation can be provided. * Endotracheal tube in place * Intubated yesterday or today * PaO2 to FIO2 ratio less than or equal to 300 while intubated * Acute opacities not fully explained by effusions, lobar/lung collapse and nodules, affecting at least one lung quadrant on chest X-ray or CT * The acute opacities on chest X-ray or CT are most likely due to COVID-19 * There is a PCR positive sample for SARS-CoV-2 within the past 21 days or there are results pending or further testing is planned. The sample can be a nasal or pharyngeal swab, sputum, tracheal aspirate, bronchoalveolar lavage, or another sample from the patient. Exclusion Criteria: * Enrolled in another clinical trial that is unapproved for co-enrolment * Heparin allergy or heparin-induced thrombocytopaenia (HIT) * APTT \> 120 seconds and this is not due to anticoagulant therapy * Platelet count \< 20 x 109 per L * Pulmonary bleeding, which is frank bleeding in the trachea, bronchi or lungs with repeated haemoptysis or requiring repeated suctioning * Uncontrolled bleeding * Pregnant or might be pregnant. Females aged 18-49 years are excluded unless there is documented menopause or hysterectomy or a pregnancy test was performed and is negative. * Receiving or about to commence extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV) * Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome * Acute brain injury that may result in long-term disability * Usually receives home oxygen * Dependent on others for personal care due to physical or cognitive decline * Death is imminent or inevitable within 24 hours * The clinical team would not be able to set up the study nebuliser and ventilator circuit as required including with active humidification * Clinician objection * Refusal of participant (person responsible) consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Frederick Health Hospital
Frederick, Maryland, 21701, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can tilting a Patient's body toward the infection help them breathe free sooner?
- COVID-19's hidden toll: muscle wasting in the ICU
- Can a mild case of COVID-19 harm your kidneys? urine tests may hold the answer
- Can a machine breathe better than a nurse? automated oxygen system tested in COPD
- Can a battery keep ventilators running during ambulance transport?